IL1B and colitis: Studies have shown that the thalidomide treatment reduce TNF-α, IL-6 and IL-1β production, and histological analysis showed considerable reduction in neutrophil infiltration and mucosal damage in colon homogenate of experimental colitis (Fakhoury et al., 2014).